Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Endo Pharmaceuticals
Endo Pharmaceuticals
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Packaging
Endo recalls one lot of Edex
Endo Pharmaceuticals has recalled one lot of Edex (alprostadil for injection) 10mcg to the consumer level, due to lack of sterility assurance
New Chief Medical Officer at Endo
Craig Paterson takes responsibility for global clinical development strategies at the company
Finance
Endo buys portfolio of branded and generic products
Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes
Finance
Endo to purchase Par Pharmaceutical for US$8.05bn
Expanding generics business, product portfolio, pipeline and manufacturing capabilities
Finance
Valeant increases offer for Salix to US$15.8bn in cash
Endo withdraws its offer for the US manufacturer of gastrointestinal drugs
Finance
Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn
Higher bid than Valeant's offer of $14.5bn in February
Pharmaceutical
Endo announces changes to senior management team
To accelerate growth both organically and through corporate development activities
Subscribe now